Supplementary Table 2. Proportions of patients experiencing adverse events over 24 weeks.

n (%)		DAPA + MET (n = 179)	SAXA + MET (n = 176)
≥ 1 Adverse event		87 (49)	93 (53)
≥ 1 Serious adverse event		2 (1)	6 (3)
Adverse events leading to discontinuation		1 (1)	0
Adverse events of special interest
	Hypoglycemia*	2 (1)	2 (1)†
	Urinary tract infection	7 (5)	9 (5)
	Genital infection	10 (6)	1 (1)
	Glomerular filtration rate decrease	0	1 (1)

^*Hypoglycemia includes minor and major;

^†Patients with more than one type of hypoglycemic episode were counted within each category but only once for patients experiencing hypoglycemia; DAPA: dapagliflozin; MET: metformin; SAXA: saxagliptin.